Company Description
ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States.
It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.
It also offers contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, including health plans, third party payers, and government organizations; and respiratory pathogen panel molecular testing services, as well as personal genomics products and services.
In addition, the company involved in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements; and retail operations.
The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.
| Country | United States |
| Founded | 1989 |
| IPO Date | Jan 16, 1997 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 113 |
| CEO | Ted William Karkus |
Contact Details
Address: 711 Stewart Ave, Suite 200, Garden City New York, New York 11530 United States | |
| Phone | (215) 345-0919 |
| Website | prophaselabs.com |
Stock Details
| Ticker Symbol | PRPH |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000868278 |
| CUSIP Number | 74345W108 |
| ISIN Number | US74345W1080 |
| Employer ID | 23-2577138 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Ted William Karkus | Chairman and Chief Executive Officer |
| Jed A. Latkin | Chief Operating Officer and Head of Finance Department |
| Robert A. Morse Jr. | Controller, Principal Financial Officer and Principal Accounting Officer |
| Sergio Miralles | Executive Vice President and Chief Information Officer |
| Jason Karkus | President of Nebula Genomics |
| Kamal Obbad | Senior Vice President and Director of Sales and Marketing - Nebula Genomics |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 18, 2024 | 8-K | Current Report |
| Mar 29, 2024 | 10-K | Annual Report |
| Mar 19, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Mar 18, 2024 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |
| Mar 15, 2024 | 8-K | Current Report |
| Jan 4, 2024 | 8-K | Current Report |
| Nov 13, 2023 | 10-Q | Quarterly Report |
| Nov 9, 2023 | 8-K | Current Report |
| Aug 11, 2023 | 10-Q | Quarterly Report |
| Aug 10, 2023 | 8-K | Current Report |